- Company
- ‘Hemlibra is the most advanced hemophilia A drug availble'
- by Nho, Byung Chul Jun 5, 2024 05:47am
- "Hemlibra has the potential to become the standard of care for hemophilia A, and is considered the most advanced treatment available." Dr. Midori Shima, professor of pediatric hematology-oncology at Nara Medical University in Japan, said so at a media session to mark the 1st anniversary of Hemlibra's insurance reimbursement extension at
- Company
- More data on Leclaza·Lorviqua showcased
- by Son, Hyung-Min Jun 5, 2024 05:47am
- Positive clinical results for targeted therapies, such as EGFR and ALK, were featured at the international conference. Clinical achievements of major targeted therapies for non-small cell lung cancer (NSCLC), including Leclaza, Rybrevant, and Lorviqua, were presented at the American Society of Clinical Oncology (ASCO 2024) annual meeting in Chic
- Company
- Sprycel patent to expire soon…market shift worth KRW 40 bil
- by Nho, Byung Chul Jun 4, 2024 05:48am
- Following the patent expiration for blockbuster medicines in the United States this year, generics are expected to enter the market. Likewise, market shifts are expected with the development and launch of generics in South Korea. According to an overseas research agency, the top 10 blockbuster medicines with patents expiring in 2024 inc
- Company
- Indication for rare cancer drug Retevmo is expanded
- by Son, Hyung-Min Jun 4, 2024 05:47am
- The indication for Retevmo, which targets a rare disease mutation in lung cancer, has been expanded to include children with solid tumors across the spectrum. Retevmo is approved in South Korea for lung cancer but not reimbursed in Korea. It will be interesting to see if the additional confirmation of clinical efficacy will have an impact on
- Company
- Evolution of ADCs… Enhertu prolongs OS in solid tumors
- by Son, Hyung-Min Jun 4, 2024 05:47am
- The antibody-drug conjugate (ADC) anticancer drug Enhertu has demonstrated further efficacy across multiple solid tumors, including HER2-low breast, biliary tract, and head and neck cancers. With the clinical results, the company secured momentum to add more solid tumors to Enhertu’s already established breast, gastric, and non-small cell
- Company
- 'Jemperli,' a PD-1 inhibitor immunotherapy lands in Big 5
- by Eo, Yun-Ho Jun 4, 2024 05:46am
- 'Jemperli,' the first immunotherapy for endometrial cancer, has landed in Big 5 general hospitals. According to industry sources, GSK Korea’s PD-1 inhibitor Jemperli (dostarlimab) has cleared the Drug Committee (DC) of the nationwide medical institutes, including Samsung Medical Center in Seoul, Seoul National University Hospital, Seo
- Company
- AbbVie’s Rinvoq is reimbursed for Crohn's Disease in KOR
- by Son, Hyung-Min Jun 3, 2024 05:49am
- Rinvoq’s reimbursement has been extended to cover Crohn's disease and ulcerative colitis in Korea. With this reimbursement extension, Rinvoq became the first and only JAK inhibitor that is reimbursed to treat adults with moderate-to-severe Crohn's disease. The treatment has been shown high effect not only in controlling symptoms but also in
- Company
- 'Dupixent,' the final stages of reimb expansion for children
- by Eo, Yun-Ho Jun 3, 2024 05:48am
- Dupixent is about to enter the last hurdle of expanding insurance reimbursement coverage for young children. According to industry sources, the Ministry of Health and Welfare (MOHW) has recently ordered drug pricing negotiations for Sanofi Korea’s Dupixent (dupilumab). Consequently, a tug-of-war between the government and Sanofi is ab
- Company
- Thrombocytopenia treatment market rises as blue ocean
- by Nho, Byung Chul Jun 3, 2024 05:48am
- The prescription market for idiopathic (immune) thrombocytopenia treatments is expected to grow exponentially with the recent reimbursement standard extension granted in Korea. Until now, reimbursement for oral immune thrombocytopenia drugs has been limited to patients with immune thrombocytopenia who are refractory to corticosteroids a
- Company
- Growing DME market…new drugs clinical trials·biosimilars
- by Son, Hyung-Min May 31, 2024 05:52am
- Korean pharmaceutical companies are challenging the market for diabetic macular edema treatments with oral formulations. Handok and Curacle confirmed effects in clinical trials for oral diabetic macular edema treatments. Because only injectables are available in the market, oral formulations can have a competitive edge because of their convenien
